As filed with the Securities and Exchange Commission on February 17, 2026 Washington, D.C. 20549 Registration No. 333- FORM S-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aspire Biopharma Holdings, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 33-3467744 (I.R.S. Employer Identification No.) 23150 Fashion Dr ...

Core Insights - Aspire Biopharma has filed a provisional patent application for a fast-acting sublingual powder formulation of ondansetron, the active ingredient in Zofran, aimed at providing rapid relief from nausea caused by cancer treatments [1] - The global ondansetron market was valued at approximately $1.4 billion in 2023 and is projected to grow to $2.4 billion by 2032, driven by increasing cancer incidences and surgical procedures [1] Company Developments - Aspire's new sublingual delivery system is designed to bypass the gastrointestinal tract, potentially reducing the onset of action from 30 minutes to just minutes, thus providing near-instant absorption [1] - The company plans to utilize the FDA's 505(b)(2) regulatory pathway to streamline clinical development and reduce time-to-market for its new formulation [1] Market Positioning - Ondansetron was the 53rd most prescribed medication in the U.S. in 2023, with over 12.5 million prescriptions, indicating significant market utilization [1] - The sublingual formulation specifically addresses the unmet need for patients who cannot swallow tablets due to severe vomiting or gastric irritation [1]

As filed with the Securities and Exchange Commission on December 3, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aspire Biopharma Holdings, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 33-3467744 (I.R.S. Employer Identification No.) 23150 Fashion Dri ...

Core Insights - Aspire Biopharma Holdings, Inc. is focusing on the commercialization of high-value approved drugs in multi-billion-dollar markets through its innovative sublingual drug delivery technology [1] Company Focus - The company is prioritizing the reformulation of approved drugs to enhance their market potential and accelerate commercialization efforts [1] - Aspire is targeting specific therapeutic areas for future platform expansion, including Central Nervous System (CNS) disorders, men's health, and anti-nausea treatments [1] Pipeline Progress - Key milestones are expected to be achieved through the remainder of 2025 and early 2026, indicating a strategic timeline for the company's development efforts [1]

As filed with the Securities and Exchange Commission on September 26, 2025 Registration No. 333-290359 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A AMENDMENT NO. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aspire Biopharma Holdings, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) Delaware 2834 33-3467744 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...

As filed with the Securities and Exchange Commission on September 18, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aspire Biopharma Holdings, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 33-3467744 (I.R.S. Employer Identification No.) 23150 Fashion D ...

As filed with the Securities and Exchange Commission on September 18, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aspire Biopharma Holdings, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 33-3467744 (I.R.S. Employer Identification No.) 23150 Fashion D ...